ABSTRACT
El plasmocitoma testicular es una neoplasia de células plasmáticas muy poco frecuente. Generalmente se trata de un hallazgo de autopsia carente de expresión clínica, aunque en algunas ocasiones puede constituir una manifestación de un mieloma múltiple y más excepcionalmente ser su única localización. La afectación bilateral es extremadamente infrecuente. Presentamos el caso de un varón de 58 años con mieloma múltiple en remisión que acude a consulta de urología por aumento progresivo del tamaño testicular bilateral. Tras realización de ecografía y PAAF testicular se diagnostica un plasmocitoma testicular bilateral. El tratamiento incluye cirugía (orquiectomía), radio y quimioterapia. El pronóstico de los pacientes depende de si se trata de un caso de plasmocitoma testicular solitario o con mieloma múltiple asociado (AU)
Testicular plasmacytoma is a very unfrequent plasma cells neoplasm. It is usually an incidental autopsy finding devoid of clinical expression, but it presents sometimes as part of a multiple myeloma and is exceptionally its only location. Bilateral involvement is extremely unfrequent. We report the case of a 58 years old man diagnosed with multiple myeloma in complete remission who complains about progressive enlargement of both testicles. After ultrasonography and PAAF, bilateral testicular plasmacytoma is diagnosed. Treatment includes surgery (orchiectomy), radiotherapy and chemotherapy. Prognostic is worse when multiplemyeloma is associated (AU)
Subject(s)
Humans , Male , Middle Aged , Plasmacytoma/diagnosis , Plasmacytoma/surgery , Multiple Myeloma/complications , Multiple Myeloma/diagnosis , Orchiectomy/methods , Plasmacytoma/drug therapy , Plasmacytoma/physiopathology , Plasmacytoma , Multiple Myeloma/pathology , Multiple Myeloma , Biomarkers/analysis , Testis/pathology , Testis , Biopsy, NeedleABSTRACT
Testicular plasmacytoma is a very unfrequent plasma cells neoplasm. It is usually an incidental autopsy finding devoid of clinical expression, but it presents sometimes as part of a multiple myeloma and is exceptionally its only location. Bilateral involvement is extremely unfrequent. We report the case of a 58-years-old man diagnosed with multiple myeloma in complete remission who complains about progressive enlargement of both testicles. After ultrasonography and PAAF, bilateral testicular plasmacytoma is diagnosed. Treatment includes surgery (orchiectomy), radiotherapy and chemotherapy. Prognostic is worse when multiple myeloma is associated.
Subject(s)
Multiple Myeloma , Neoplasms, Second Primary , Plasmacytoma , Testicular Neoplasms , Humans , Male , Middle Aged , Multiple Myeloma/therapy , Neoplasms, Second Primary/diagnosis , Neoplasms, Second Primary/therapy , Plasmacytoma/diagnosis , Plasmacytoma/therapy , Testicular Neoplasms/diagnosis , Testicular Neoplasms/therapyABSTRACT
OBJETIVO: El Tumor Fibroso Solitario (TFS) es una neoplasia poco frecuente que fue descrita por primera vez en la pleura, pero puede aparecer en diferentes localizaciones. Su presencia en la zona inguinal es extremadamente rara. MÉTODO/RESULTADOS: Presentamos el caso de un varón de 74 años con masa inguinoescrotal derecha de 50 años de evolución. Tras extirpación quirúrgica de la misma es diagnosticado de tumor fibroso solitario. CONCLUSIONES: La inmensa mayoría de los tumores fibrosos solitarios se comportan de manera benigna. Un pequeño porcentaje se comporta de modo más agresivo, con recurrencia local y metástasis. Su tratamiento es eminentemente quirúrgico, pero después debemos realizar seguimiento a largo plazo en todos los casos (AU)
OBJECTIVE: Solitary fibrous tumours (SFTs) are rare neoplasias that were first reported in pleura, but can occur in different sites. Inguinal location is extremely rare. METHODS/RESULTS: We report one case of a 74 year old man with a right inguinoscrotal mass with 50 years of evolution. After surgical extirpation, solitary fibrous tumour was diagnosed. CONCLUSIONS: The vast majority of solitary fibrous tumours (SFTs) have a benign course. Only a few cases have aggressive behaviour, with local recurrence and metastasis. Treatment is surgical, but we must do a long-term follow up in all cases (AU)
Subject(s)
Humans , Male , Aged , Inguinal Canal , Solitary Fibrous Tumors/diagnosisABSTRACT
OBJECTIVE: Solitary fibrous tumours (SFTs) are rare neoplasias that were first reported in pleura, but can occur in different sites. Inguinal location is extremely rare. METHODS/RESULTS: We report one case of a 74 year old man with a right inguinoscrotal mass with 50 years of evolution. After surgical extirpation, solitary fibrous tumour was diagnosed. CONCLUSIONS: The vast majority of solitary fibrous tumours (SFTs) have a benign course. Only a few cases have aggressive behaviour, with local recurrence and metastasis. Treatment is surgical, but we must do a long-term follow up in all cases.
Subject(s)
Inguinal Canal , Solitary Fibrous Tumors/diagnosis , Aged , Humans , MaleABSTRACT
OBJECTIVE: Since its discovery as a marker for prostate cancer, there have been many attempts to enhance the diagnostic efficacy of the prostate specific antigen (PSA). Among these are the studies that analyze the behavior of different forms of serum PSA bound to different antiproteases, such as alpha-1-antichymotrypsin, which forms the complexed PSA (PSA-c). This study analyzed the utility of PSA-c to enhance specificity without altering sensitivity in comparison to total PSA (PSA-t). METHODS: From September 1998 to March 1999, blood samples were obtained from 96 patients that had undergone a prostate biopsy due to a suspicion of prostate cancer. PSA-c, PSA-t (Technicon Immunol system, Bayer) and PSA-c/PSA-t ratio were analyzed in these patients. RESULTS: ROC curves were plotted and the optimal cutoffs were found for which the specificity was higher for PSA-c (44.6% [CI 95%, 32-57]) versus PSA-t (35.4% [CI 95%, 25-49]) and the PSA-c/PSA-t ratio (38.5% [CI 95%, 27-51]) while maintaining a similar sensitivity index (90%). PSA-c showed similar results for other values of sensitivity. CONCLUSIONS: PSA-c was found to improve specificity in comparison to PSA-t and PSA-c/PSA-t ratio. PSA-c determination could avoid unnecessary biopsies without altering sensitivity; i.e., the same number of prostate cancers will be detected.
